Allergy· 2021Q1· Guideline
EAACI guidelines: Anaphylaxis (2021 update)
- 580citations
- Q1SCImago
- 2021year
Short summary
The 2021 EAACI Anaphylaxis guideline recommends using clinical criteria for diagnosis, supported by later tryptase measurement, and prioritizes immediate intramuscular adrenaline as first-line treatment, with readily available autoinjectors for community use.
AI-generated from the title and abstract; the full text is not read.
Key points
- Recommends clinical criteria for anaphylaxis diagnosis, with optional later tryptase measurement.
- Prioritizes immediate intramuscular adrenaline as first-line management.
- Advocates for widespread availability of adrenaline autoinjectors for community use.
- Suggests structured training for at-risk individuals and simulation training for healthcare professionals.
- Highlights the low level of evidence and the need for more clinical trials.
AI-generated from the title and abstract; the full text is not read.
Abstract
Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognize and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline. The guideline was developed using the AGREE II framework and the GRADE approach. The evidence was systematically reviewed and recommendations were created by weighing up benefits and harms. The guideline was peer-reviewed by external experts and reviewed in a public consultation. The use of clinical criteria to identify anaphylaxis is suggested with blood sampling for the later measurement of tryptase. The prompt use of intramuscular adrenaline as first-line management is recommended with the availability of adrenaline autoinjectors to patients in the community. Pharmacokinetic data should be provided for adrenaline autoinjector devices. Structured, comprehensive training for people at risk of anaphylaxis is recommended. Simulation training and visual prompts for healthcare professionals are suggested to improve the management of anaphylaxis. It is suggested that school policies reflect anaphylaxis guidelines. The evidence for the management of anaphylaxis remains mostly at a very low level. There is an urgent need to prioritize clinical trials with the potential to improve the management of patients at risk of anaphylaxis.
The authors' abstract, as published at the source. Allergy, 2021 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Immunology and Allergy
Immunology and AllergyMedicine